Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2

被引：17

作者：

Anifowose, Abiodun ^{[1
,2
]}

Agbowuro, Ayodeji A. ^{[1
,2
]}

Yang, Xiaoxiao ^{[1
,2
]}

Wang, Binghe ^{[1
,2
]}

机构：

[1] Georgia State Univ, Dept Chem, Petit Sci Ctr, 100 Piedmont Ave, Atlanta, GA 30303 USA

[2] Georgia State Univ, Ctr Diagnost & Therapeut, Petit Sci Ctr, 100 Piedmont Ave, Atlanta, GA 30303 USA

来源：

MEDICINAL CHEMISTRY RESEARCH | 2020年 / 29卷 / 07期

基金：

美国国家卫生研究院;

关键词：

p53; MDM2; Small-molecule inhibitors; restoration; STRUCTURE-BASED DESIGN; TARGETED PROTEIN-DEGRADATION; SMALL-MOLECULE RITA; CELL-CYCLE ARREST; TRANSCRIPTIONAL ACTIVATION; STAPLED P53; CANCER; APOPTOSIS; DOMAIN; DISCOVERY;

D O I：

10.1007/s00044-020-02574-9

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The potentiation of p53 activity through inhibition of its negative regulator MDM2 is an attractive strategy for anticancer therapy. Much progress has been made in the last decade in a diverse range of areas related to p53 and MDM2. This review focuses on the recent progress in developing small-molecule inhibitors of the MDM2 protein by covering the following approaches that inhibit the function of the p53-MDM2 axis: (1) direct binding to MDM2, (2) direct binding to p53, (3) targeted degradation of MDM2 by the PROTAC approach, and (4) inhibition of MDM2/MDM4 interaction. Given the importance of p53 in cancer development, we hope that research in this area will lead to anticancer drugs in the not too distant future.

引用

页码：1105 / 1121

页数：17

共 122 条

[41] Targeting protein-protein interactions as an anticancer strategy [J].

Ivanov, Andrei A. ;

Khuri, Fadlo R. ;

Fu, Haian .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2013, 34 (07) :393-400

[42] Regulation of p53 expression by thymidylate synthase [J].

Ju, JF ;

Pedersen-Lane, J ;

Maley, F ;

Chu, E .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3769-3774

[43] The Roles of MDM2 and MDMX in Cancer [J].

Karni-Schmidt, Orit ;

Lokshin, Maria ;

Prives, Carol .

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11, 2016, 11 :617-644

[44] P53, CELL-CYCLE CONTROL AND APOPTOSIS - IMPLICATIONS FOR CANCER [J].

KASTAN, MB ;

CANMAN, CE ;

LEONARD, CJ .

CANCER AND METASTASIS REVIEWS, 1995, 14 (01) :3-15

[45] Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c [J].

Korsmeyer, SJ ;

Wei, MC ;

Saito, M ;

Weller, S ;

Oh, KJ ;

Schlesinger, PH .

CELL DEATH AND DIFFERENTIATION, 2000, 7 (12) :1166-1173

[46] NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro [J].

Krajewski, M ;

Ozdowy, P ;

D'Silva, L ;

Rothweiler, U ;

Holak, TA .

NATURE MEDICINE, 2005, 11 (11) :1135-1136

[47] Modes of p53 Regulation [J].

Kruse, Jan-Philipp ;

Gu, Wei .

CELL, 2009, 137 (04) :609-622

[48] Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain [J].

Kussie, PH ;

Gorina, S ;

Marechal, V ;

Elenbaas, B ;

Moreau, J ;

Levine, AJ ;

Pavletich, NP .

SCIENCE, 1996, 274 (5289) :948-953

[49] Small molecule activators of the p53 response [J].

Ladds, Marcus J. G. W. ;

Lain, Sonia .

JOURNAL OF MOLECULAR CELL BIOLOGY, 2019, 11 (03) :245-254

[50] Induced protein degradation: an emerging drug discovery paradigm [J].

Lai, Ashton C. ;

Crews, Craig M. .

NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (02) :101-114

← 1 2 3 4 5 6 7 8 9 10 →